Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
2.140
-0.060 (-2.73%)
Mar 31, 2025, 9:30 AM EST - Market open
Perspective Therapeutics Employees
As of December 31, 2024, Perspective Therapeutics had 140 total employees, including 138 full-time and 2 part-time employees. The number of employees increased by 21 or 17.65% compared to the previous year.
Employees
140
Change (1Y)
21
Growth (1Y)
17.65%
Revenue / Employee
$12,218
Profits / Employee
-$666,210
Market Cap
158.47M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CATX News
- 6 hours ago - Perspective Therapeutics to Participate in Upcoming April Investor Conferences - GlobeNewsWire
- 4 days ago - Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results - GlobeNewsWire
- 14 days ago - Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - GlobeNewsWire
- 17 days ago - Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst - Benzinga
- 4 weeks ago - Perspective Therapeutics to Present at Upcoming March Investor Conferences - GlobeNewsWire
- 5 weeks ago - Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Perspective Therapeutics to Participate in Upcoming February Investor Conferences - GlobeNewsWire
- 2 months ago - Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium - GlobeNewsWire